CHRS

Quarterly Performance: Coherus Oncology reported a quarterly loss of $0.33 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.32, and significantly down from a loss of $0.01 per share a year ago.

Revenue Miss: The company generated revenues of $11.57 million for the quarter, missing the consensus estimate by 5.23% and down from $70.77 million in the same quarter last year.

Stock Outlook: Coherus Oncology's stock has underperformed compared to the S&P 500 this year, and its future performance will depend on management's commentary and earnings estimate revisions, currently holding a Zacks Rank #3 (Hold).

Industry Context: The Medical - Biomedical and Genetics industry is ranked in the top 41% of Zacks industries, indicating potential for better performance, while another industry peer, Armata Pharmaceuticals, is expected to report a significant loss in its upcoming results.

Upcoming Conferences: Coherus Oncology will webcast presentations at the UBS Global Healthcare Conference on November 10, 2025, the Jefferies Global Healthcare Conference on November 18, 2025, and the Baird Biotech Discovery Series on December 17, 2025, with replays available for 30 days.

Company Overview: Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline of mid-stage clinical candidates targeting various cancers, aiming to grow sales and develop new indications.

Innovative Pipeline: The company's pipeline includes antibody immunotherapy candidates like CHS-114, currently in Phase 1b/2a studies, and Casdozokitug, being evaluated in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors.

Disclosure Practices: Coherus utilizes its website for disclosing material non-public information and complies with Regulation FD, ensuring transparency with investors.